La vendita allo scoperto per Galera Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Galera Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Galera Therapeutics (OTC:GRTX) Azioni, Report sulle vendite allo scoperto

Galera Therapeutics

Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. The Firm's lead product candidate, avasopasem manganese, is a highly selective small molecule dismutase mimetic for severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Firm's second product candidate, rucosopasem manganese, has been in development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).

GALERA THERAPEUTICS INC by Galera Therapeutics, Inc.

Galera Therapeutics Inc

News

SPPL

SIMPPLE Outlines Plan To Regain Nasdaq Compliance, Including Potential Reverse Stock Split; Requests Hearing With Nasdaq To Seek Extension While Continuing Business Operations And Securing New Contracts

SI-BONE, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>), a&nbsp;Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for the iFuse Bedrock Granite&#x2122; (Granite) system, used for pelvic fixation and sacroiliac joint fusion in conjunction with lumbar spinal fusion procedures, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment status, which will be effective up to three years beginning January 1, 2025, allows patient access to new and innovative technology like Granite by providing an add-on payment to hospitals and ambulatory surgery centers supporting it.
As part of the TPT determination, CMS confirmed that a customary deduction from the add-on payment, known as a device offset, will not be applied to lumbar spinal fusion procedures involving pelvic fixation with Granite. This decision recognizes that Granite costs are not currently included in the existing facility payment amount for the procedures using this technology.

Biotech

General

SIBN

SI-BONE Receives Transitional Pass-Through Payment Status For iFuse Bedrock Granite System, Used For Pelvic Fixation And Sacroiliac Joint Fusion In Conjunction With Lumbar Spinal Fusion Procedures, Under The Medicare Hospital Outpatient Prospective Payment System

Simpple Ltd, A Leading Technology Provider Announced Its Plan To Regain NASDAQ Compliance

Guidance

BLDP

Ballard Power Systems Expects Revenue In 2024 To Be Weighted Towards Q4

The New York State Common Retirement Fund has significantly reduced its stake in Vistra Corp., according to a recent filing with the Securities &amp; Exchange Commission (SEC). This move was executed during the third quarter.
What Happened: The fund divested 43,440 shares, marking a 21.6% reduction in its Vistra Corp. holdings. Following this transaction, the fund retains 157,565 shares of the company&#8217;s stock, valued at $18,678,000 as per the latest SEC filing. This adjustment is part of the fund&#8217;s broader portfolio management strategy.
The change in the portfolio comes at a time when Vistra Corp&#8217;s year-to-date (YTD) returns have crossed 200%. As per Benzinga Pro, Vistra Corp was trading 0.24% higher on Tuesday during pre-market than its previous day close at $115.74.
See Also: <a href="https://www.benzinga.com/news/24/11/41705158/cathie-wood-says-trumps-ideas-on-eliminating-income-tax-and-imposing-tariffs-brings-back-vibes-of-ea?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Says Trump&#8217;s Ideas On Eliminating Income Tax And Imposing Tariffs Brings Back Vibes Of &#8216;Early</a>
Why It Matters: Texas-based Vistra Corp. <a href="https://www.benzinga.com/insights/news/24/11/41715992/evaluating-vistra-against-peers-in-independent-power-and-renewable-electricity-producers-industry">stands as a major player</a> in the Independent Power and Renewable Electricity Producers industry. It is one of the largest power producers and retail energy providers in the U.S., especially after acquiring Energy Harbor in 2024. This acquisition expanded Vistra&#8217;s portfolio to include 41 gigawatts of nuclear, coal, natural gas, and solar power generation, alongside one of the world&#8217;s largest utility-scale battery projects.
Vistra&#8217;s retail electricity business serves approximately 5 million customers across 20 states, covering nearly a third of Texas&#8217;s electricity consumers. The company emerged as an independent entity in 2016 after the bankruptcy of Energy Future Holdings and further expanded by acquiring Dynegy in 2018.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41705665/palantir-technologies-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Palantir Technologies Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Top Analysts</a></li>
</ul>
Image via Midjourney
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Equities

Markets

New York State Common Retirement Fund Pares Vistra Corp Stake After Shares Rally Over 200% This Year

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced that ART26.12, the Company's lead clinical FABP inhibitor, has been accepted into the NIH Helping to End Addiction Long Term (HEAL) Initiative's Preclinical Screening Platform for Pain (PSPP).
The HEAL Initiative is an NIH-wide effort to accelerate scientific solutions to the overdose epidemic, including opioid and stimulant use disorders, and the crisis of pain. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOgSxpFF0XIvawVscW4wbdwg7V_FhA3Ltt3AEUAniLYFzGCWmQxbGtaOlCTeoy9z_gw==">https://heal.nih.gov</a>.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics,&nbsp;devices,&nbsp;or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: <a href="https://www.globenewswire.com/Tracker?data=V0OIqyLfFcY5W7pjPpAuOlGjlyIIOqxGCXGg7oAt6Z8k_ceVEneHLI1vwxQ_6cUhkiltyTw8QQT1pV5d70643HL2HPZdhRFfxJaV9YNhfRmH9nfw_RF6CKHtAfA4IrI-OAUc2GDix2f8AgJTeD-gGsZnWraYf9DQLl_KK0KyPERmmZ2qiTanbmibjkbPuCBhaatGJ8TqR2NK9mw7c9BFBPeEx1kzbGwZK3J_7R1YWB0=">https://heal.nih.gov/research/preclinical-translational/screening-platform</a>.
The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

ARTL

Artelo Biosciences Announces Acceptance Of ART26.12 Into The National Institutes Of Health's Helping To End Addiction Long Term Initiative's Preclinical Screening Platform For Pain

WIIM

MPLX

MPLX shares are trading higher. The company reported Q3 financial results.

TCMD

Tactile Systems Tech shares are trading lower after BTIG downgraded the stock from Buy to Neutral.

Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.13) by 423.08 percent. The company reported quarterly sales of $14.800 million which missed the analyst consensus estimate of $23.556 million by 37.17 percent. This is a 46.33 percent decrease over sales of $27.575 million the same period last year.

Earnings

Earnings Misses

Ballard Power Systems Q3 2024 GAAP EPS $(0.68) Misses $(0.13) Estimate, Sales $14.800M Miss $23.556M Estimate

UL Solutions shares are trading higher after the company reported better-than-expect Q3 financial results.

<a href="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss" title="https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss">https://www.statnews.com/2024/11/05/patient-dies-sickle-cell-beam-therapeutics-crispr/?utm_campaign=rss</a>

BEAM

Patient In Beam Therapeutics' CRISPR Trial For Sickle Cell Disease Dies From Likely Chemotherapy Complications; Early Signs Of Gene Editing Effectiveness Observed In Other Participants

Management

PHUN

Phunware Names Rahul Mewawalla As Chairman Of The Board To Lead Growth And Innovation In AI, Predictive Analytics, And Cloud Services

Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer (HNSCC). In a presentation at Society for Immunotherapy of Cancer's Annual Meeting (SITC) on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study (NCT04815720) for treatment of recurrent and metastatic disease as well as an independent study evaluating neoadjuvant treatment of resectable HNSCC (NCT03690986) showing that pepinemab combination treatments appear to induce mature lymphoid aggregates correlating with clinical benefit within immunotherapy resistant tumor populations, including HPV-negative and PD-L1 low HNSCC.

VCNX

Vaccinex Reports Improved Immunity Correlating With Clinical Benefit Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer's Annual Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Buy and raises the price target from $36 to $42.

Price Target

Analyst Ratings

VRNA

HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $42

JP Morgan analyst Matthew Boss maintains Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Neutral and lowers the price target from $97 to $82.

JP Morgan Maintains Neutral on Dollar Gen, Lowers Price Target to $82

Expeditors Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NASDAQ">EXPD</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.35 by 20.74 percent. The company reported quarterly sales of $3.000 billion which beat the analyst consensus estimate of $2.444 billion by 22.76 percent. This is a 36.99 percent increase over sales of $2.190 billion the same period last year.

Earnings Beats

EXPD

Expeditors Intl Q3 2024 GAAP EPS $1.63 Beats $1.35 Estimate, Sales $3.000B Beat $2.444B Estimate

CSLR

Complete Solar Sees Prelim. Q3 Revenue $117.3M

Macro Economic Events

Econ #s

Economics

USA Exports 267.95B; 271.80B Prior

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) has big dreams for a <a href="https://www.benzinga.com/topic/hydrogen">green hydrogen-powered future</a>, but it might hit some potholes before reaching that destination. 
JPMorgan's Bill Peterson brings a cautiously balanced view, signaling that while Plug Power's ambitions shine bright, the near-term realities could dampen the sparkle for investors. As we speed toward the company's third-quarter earnings call on Nov. 12 and its annual Plug Symposium on Nov. 13, expectations are mixed, with both high hopes and real risks.
<h2 class="wp-block-heading">Watch For Roadblocks Heading Into H2</h2>
Plug Power has set its sights high, predicting substantial growth in its hydrogen-driven Energy business and aiming to double revenue in the second half of 2024. 
However, hitting these targets will require a serious acceleration in sales—especially in the softer material handling sector and a reliable revenue boost in electrolyzer equipment. But with a sluggish U.S. hydrogen market and the 45V tax credit still a question mark, this quarter's results may land below expectations, with Plug likely to fall short of the high double-digit growth needed to meet the lower end of its guidance range, the analyst said.
Read Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41713236/donald-trumps-return-to-white-house-could-propel-these-etfs-to-new-highs" target="_blank" rel="noreferrer noopener">Donald Trump's Return To White House Could Propel These ETFs To New Highs</a>
<h2 class="wp-block-heading">The Symposium Spotlight: A Blueprint For Long-Term Growth</h2>
At the upcoming Plug Symposium, management is expected to emphasize its roadmap beyond quarterly earnings.
Plug Power could unveil its vision for reaching $20 billion in revenue by 2030, a bold ambition that Peterson considers likely to face practical constraints. While the Symposium may inspire with case studies in hydrogen applications and potential growth in mobility and stationary power, Plug will need to prove its green hydrogen network can yield real profits, especially as global interest in hydrogen faces increasing skepticism around commercial viability.
<h2 class="wp-block-heading">Short-Term Jitters With A Dash Of Optimism</h2>
Plug Power's short-term outlook carries a dose of volatility, partly fueled by ongoing political uncertainty. The company may reiterate its guidance, but Peterson remains unconvinced it's achievable, seeing risks in the 2024 market landscape.
Although PLUG stock's 28% short interest reflects broad market wariness, a clear policy signal or an unexpected DOE loan closure could still spark some interest. For now, though, Plug is under pressure to execute margin improvements and make tangible progress on cash flow management before it can comfortably court long-term investors.
<h2 class="wp-block-heading">Staying Neutral, But Watching The Horizon</h2>
JPMorgan's Peterson is staying neutral on PLUG, balancing near-term headwinds with the potential long-term upside if hydrogen gains a foothold. 
While Plug Power's green hydrogen goals are audacious, the company faces cash flow and demand challenges that can't be overlooked. 
For investors, the message is clear: stay buckled up for a bumpy ride, and don't lose sight of the possible rewards if Plug Power can overcome its hurdles and secure a sustainable path forward in the green hydrogen revolution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/esg/24/11/41722922/trump-vs-harris-evgo-cleveland-cliffs-plug-power-nucor-brace-for-2024-election-impact">Trump Vs. Harris: EVgo, Cleveland-Cliffs, Plug Power, Nucor Brace For 2024 Election Impact</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Trading Ideas

PLUG

Plug Power's $20 Billion Revenue Ambition Faces Obstacles, Analyst Says

Colony Bankcorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAN#NASDAQ">CBAN</a>) ("Colony" or the "Company") the parent company of Colony Bank, announced today that it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from The Nasdaq Stock Market LLC (Nasdaq).
Colony Bankcorp's common stock is expected to begin trading on the NYSE on November 18, 2024, under the ticker symbol of "CBAN." Colony Bankcorp expects its common stock to continue to trade on Nasdaq until the close of the market on November 15, 2024.

CBAN

Colony Bankcorp Announces Transfer Of Listing Of Common Stock To The NYSE From The Nasdaq Stock Market; Expected To Begin Trading On The NYSE On November 18, 2024

Galera Therapeutics GAAP EPS of -$0.10

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!



Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li>Vanda Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li>VIA Optronics (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/">VIAO</a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li>Chromocell Therapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/">CHRO</a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li>CXApp (NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/">CXAI</a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li>Seelos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/">SEEL</a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li>Mobile Global Esports (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/">MGAM</a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is jumping 21% despite a lack of news today.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Trilogy Metals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/">TMQ</a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li>Trio Petroleum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/">TPET</a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li>Ontrak (NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/">OTRK</a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li>Ryvyl (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/">RVYL</a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li>iSun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Galera Therapeutics (GRTX) has issued an update. Galera Therapeutics, Inc. has implemented a stockholder rights plan, issuing one Right per common ...

Galera Therapeutics Enacts Plan to Deter Hostile Takeovers

Galera Therapeutics GAAP EPS of -$0.08

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) just reported results for the first quarter of 2024.<ul><li>Galera Therapeutics reported earnings per share of -8 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/grtx-stock-earnings-galera-therapeutics-for-q1-of-2024/">GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q1 2024

Galera Therapeutics (GRTX) has provided an update. Galera Therapeutics, Inc. is streamlining its operations amidst a strategic review by eliminatin...

Galera Therapeutics Restructures Leadership and Cuts Costs

Galera Therapeutics (GRTX) just unveiled an announcement. Galera Therapeutics, Inc. recently settled a lawsuit against two Clinical Research Organi...

Galera Therapeutics Settles Clinical Trial Dispute Lawsuit

Galera Therapeutics (GRTX) has shared an update. Galera is set to dissolve and wind up its business, a decision made by the Board to benefit the sh...

Galera Therapeutics Announces Wind-Up and Special Stockholder Meeting

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) just reported results for the second quarter of 2024.<ul><li>Galera Therapeutics reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/grtx-stock-earnings-galera-therapeutics-for-q2-of-2024/">GRTX Stock Earnings: Galera Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GRTX Stock Earnings: Galera Therapeutics Reported Results for Q2 2024

AILE

BPTS

BSGM

CHRO

CLNN

CXAI

DFLI

DRMA

DXYZ

DYNT

EZFL

GPAK

GRTX

HEPA

HGAS

HUBC

INDO

INVO

ISUN

MGAM

MLEC

OTRK

PALI

PRTG

RVYL

RWOD

SBFM

SEEL

SOAR

SPCB

TPET

VAXX

VIAO

VNDA

YYAI

Press Releases

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Galera Adopts Limited Duration Stockholder Rights Agreement

Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

Comments

Galera Therapeutics

Vendite allo scoperto

Galera Therapeutics (OTC:GRTX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO